Light Mode
$3.04 ↑ +0.00 (+0.00%) Trading Up from the previous close of $3.04, $0.22 below the day’s high of $3.26
+0.31 (+11.36%) / 6M
Momentum, market sentiment, and recent alerts
TCRT reads neutral: price sits above both the 20- and 200-day averages, the 12-month move is +18.8%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Fort Lauderdale, FL.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.